Olaparib (Lynparza®) in combination with abiraterone and prednisone. HTA ID: 23029

Assessment Status Awaiting response from Applicant
HTA ID 23029
Drug Olaparib
Brand Lynparza®
Indication Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated
Assessment Process
Rapid review commissioned 31/05/2023
Rapid review completed 13/06/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with abiraterone and prednisone or prednisolone compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/06/2023
Pre-submission consultation with Applicant 09/08/2023
Full submission received from Applicant 31/01/2024
Preliminary review sent to Applicant 21/11/2024